# Copilot Chat — Complete Outputs (AG-UI surface, 2026-07-29)

Every question from docs/demos/COPILOT_CHAT_DEMO_SCENARIOS.md asked against the real UI brain
(`POST /api/copilotkit/agent/default`). Timings are client-measured; `grade` = latency vs the
tier budget (T1<3s, T2<8s, T3<40s, T4<90s; T5/T6 graded on behavior, see SUMMARY).


---

## Session `n1`

### 1.1 — T2 · PASS
**Q:** What is TRx for Kisqali?
*ttfb 7.4062s · first_progress 7.3976999999999995s · total 7.4079s · tools: kpi_calculate_tool*

> **Kisqali TRx: 13,242 total prescriptions**
> 
> - **Source**: WS3-BI-005 (synthetic data)
> - **Window**: Most recent 30 days of prescription data, through 2026-07-27 (this is the engine's default reporting window, not a specific period you requested)
> 
> Let me know if you'd like a breakdown by patient segment or line of therapy, or a comparison to a prior period.

### 1.2 — T2 · PASS
**Q:** What are the TRx trends for Kisqali in Q4?
*ttfb 7.093100000000001s · first_progress 7.0856s · total 7.0955s · tools: kpi_calculate_tool*

> **Kisqali TRx for Q4 2025 (Oct 1 – Dec 31, 2025): 872 total prescriptions**
> 
> - **Source**: WS3-BI-005 (synthetic data)
> - **Window**: Full Q4 2025, as requested — 92 days, applied exactly as specified.
> 
> Note: this is a single aggregate total for the quarter, not a month-by-month trend line — the tool doesn't return an internal breakdown within the window. If you want to see the actual trend (e.g., month-over-month movement within Q4), I can pull the monthly KPI history via a chart, or I can compare Q4 2025 to a prior non-overlapping quarter (e.g., Q3 2025) to gauge direction. Let me know which you'd prefer.

### 1.3 — T2 · OVER (8.1s > 8s)
**Q:** What is the market share for Kisqali compared to competitors?
*ttfb 8.134s · first_progress 8.1316s · total 8.1364s · tools: kpi_calculate_tool*

> **Kisqali TRx Share: 30.9%**
> 
> - **Source**: WS3-BI-008 (synthetic data)
> - **Window**: Most recent 30 days of prescription data, through 2026-07-27 (the engine's default reporting window — not Q4 2025, which you asked about earlier)
> 
> Important clarification: this figure is **not** market share versus external competitors. It's Kisqali's share of the *tracked portfolio* — i.e., prescriptions across Kisqali + Fabhalta + Remibrutinib combined (cross-indication brands Novartis tracks in this system). Competitors like Ibrance, Verzenio, or other CDK4/6 inhibitors are not in this data model, so I can't quantify Kisqali's share of the actual breast cancer market or attribute the remaining ~69% to any named competitor.
> 
> If you want, I can pull TRx share trended over time via a chart, or break down Kisqali's TRx by segment/line of therapy within the tracked portfolio.

### 1.4 — T3 · PASS
**Q:** Why did Kisqali TRx drop in Q1 in the northeast region?
*ttfb 19.0412s · first_progress 7.7827s · total 19.0478s · tools: kpi_calculate_tool*

> **Kisqali TRx in the Northeast — Q1 2026 vs. Q4 2025:**
> 
> - **Q1 2026 (Jan 1 – Mar 31, 2026): 126 prescriptions**
> - **Q4 2025 (Oct 1 – Dec 31, 2025): 141 prescriptions**
> 
> That's a **decline of ~10.6%** quarter-over-quarter in the Northeast — both windows are non-overlapping full quarters, so this is a valid trend comparison.
> 
> **Likely drivers (from causal analysis, Kisqali/Northeast, confidence ≥0.7):**
> 
> | Driver | Effect on TRx | Confidence | Est. Business Impact |
> |---|---|---|---|
> | Competitor activity → market share (via share of voice) | **-0.073** (negative) | 0.793 | -$24,218 |
> | HCP coverage → market share (via prescriber base) | +0.09 | 0.899 | +$29,541 |
> | Persistent 180d refill continuity → volume | +0.285 | 0.892 | +$127,512 |
> | Formulary status → volume (via patient access) | +0.223 | 0.805 | +$100,658 |
> | Rep detailing frequency → volume (via HCP engagement) | +0.166 | 0.796 | +$38,244 |
> | Copay support program → volume (via adherence) | +0.088 | 0.794 | +$17,025 |
> 
> The one factor with a **negative** effect size is **competitor activity** — increased competitive detailing/share-of-voice is associated with a share erosion of -0.073, which aligns with a drop. All other drivers listed are positive contributors, meaning if they *weakened* (e.g., reduced rep detailing frequency, formulary friction, lower HCP coverage) rather than strengthened, that could also explain the decline — the causal engine identifies them as levers, not necessarily confirming they moved unfavorably in Q1.
> 
> **Supporting signal**: One active trigger in the region flags a **"competitive_threat"** (critical priority, confidence 0.737) — "Recent competitive detailing detected" — reinforcing competitor activity as a contributing factor. Note this trigger is dated July 2026 (current reporting window), not Q1 2026 itself, so treat it as corroborating context rather than direct proof for that quarter.
> 
> **Bottom line**: The data points most strongly to **competitor share-of-voice pressure** as the identified negative driver, with the size of the drop also consistent with softening in HCP coverage, rep detailing, or formulary access — those weren't directly measured as *declining* in this pull, just identified as positive levers whose weakening would produce this effect.
> 
> Want me to check HCP coverage or rep detailing trends specifically for Northeast in Q1 to confirm which lever actually moved?

### 1.5 — T3 · PASS
**Q:** What is the causal impact of rep visits on TRx for Kisqali?
*ttfb 7.857s · first_progress 7.845899999999999s · total 7.8602s · tools: causal_analysis_tool*

> **Rep detailing frequency → Kisqali TRx volume**
> 
> - **Effect size: +0.166** (via HCP engagement pathway)
> - **Confidence: 0.796**
> - **Estimated business impact: +$38,244**
> - **Time lag: ~77 days** (effect materializes roughly 2.5 months after detailing activity)
> - **Source**: Causal paths registry (synthetic data), Kisqali, min confidence 0.5
> 
> **Interpretation**: Increased rep detailing frequency is associated with a positive, moderately-sized lift in TRx volume, mediated through greater HCP engagement. It's one of six identified causal drivers for Kisqali TRx, ranking third by effect size — behind persistent 180-day refill continuity (+0.285) and formulary status (+0.223), but ahead of copay support (+0.088).
> 
> This is a general causal relationship from the registry (not tied to a specific quarter or region you asked about earlier — e.g., Northeast Q1 2026); it reflects the modeled relationship across the brand overall.
> 
> Let me know if you'd like this narrowed to the Northeast region or Q1 2026 specifically.

### 1.6 — T5 · n/a
**Q:** Which HCP segments show the strongest effect?
*ttfb 12.6534s · first_progress 12.5397s · total 12.657200000000001s · tools: e2i_data_query_tool*

> **HCP segment-level breakdown isn't available for this query.**
> 
> - The `heterogeneous_optimizer` agent analysis (which would typically surface segment-differentiated treatment effects) returned **zero results** for Kisqali — no data currently populated for that agent's HCP-segment analysis.
> - The causal registry doesn't split rep-detailing effects by HCP segment (e.g., high-vs-low prescriber tier, academic vs. community). It does return related rep-detailing pathways for Kisqali overall:
> 
> | Cause → Effect | Effect Size | Confidence | Time Lag | Business Impact |
> |---|---|---|---|---|
> | Rep detailing → intent to prescribe (via message recall) | **+0.267** | 0.772 | 35 days | +$119,357 |
> | Rep detailing → ROI (via TRx volume) | +0.198 | 0.851 | 40 days | +$59,581 |
> | Rep detailing → TRx volume (via HCP engagement) | +0.166 | 0.796 | 77 days | +$38,244 |
> | Rep detailing high → treatment initiated | +0.043 | 0.93 | 8 days | +$6,432 |
> 
> **Bottom line**: Across all six causal paths returned, the strongest rep-detailing effect is on **intent to prescribe** (+0.267, via message recall), suggesting detailing's biggest lever is shaping prescribing intent before it converts to volume — but I can't tell you *which HCP segment* (e.g., by prescribing volume tier or specialty) drives this most strongly, since that breakdown isn't populated in the current data. If useful, I can check the standard segment axis (low/medium/high severity) or therapy-line breakdown for TRx instead, though that reflects patient segments, not HCP segments.

### 1.7 — T5 · n/a
**Q:** Based on that, how should we reallocate rep effort next quarter?
*ttfb 14.6835s · first_progress 4.6617s · total 14.6865s · tools: e2i_data_query_tool*

> **Rep effort reallocation for Kisqali — Q3 2026 planning**
> 
> Note upfront: the recommendation tool didn't return specific rep-targeting actions — it surfaced regional TRx performance snapshots (June/July 2026) instead. Combining that with the causal drivers already established, here's a data-grounded reallocation logic:
> 
> **Regional performance (TRx, June–July 2026, vs. target):**
> 
> | Region | TRx | Target | Achievement | YoY | ROI |
> |---|---|---|---|---|---|
> | Midwest | 213,916 | 219,011 | **97.7%** | +17.9% | 2.63 |
> | South | 203,508 | 215,586 | **94.4%** | +30.0% | **2.89** |
> | Northeast | 252,475 | 269,839 | **93.6%** | +28.3% | 1.86 |
> | West | 160,203 | 231,136 | **69.3%** (largest gap) | +25.1% | 1.64 |
> 
> **Reallocation logic:**
> 
> 1. **Shift incremental rep effort toward West** — it has the largest achievement gap (69.3% vs. target) and lowest ROI (1.64). Since rep detailing's strongest causal effect is on *intent to prescribe* (+0.267) with an ~35-day lag, increased detailing here has the most room to convert underperformance into volume, though the payback (ROI) may lag other regions initially.
> 
> 2. **Protect/maintain South** — highest ROI (2.89) and strong YoY growth (+30%), suggesting current rep effort there is highly efficient. Don't cut here even though it's near target.
> 
> 3. **Northeast is a caution zone** — it's the region flagged earlier with a critical "competitive_threat" trigger (competitor share-of-voice pressure) and a Q1 2026 TRx decline. Despite decent volume, ROI is comparatively low (1.86) and share is being contested — targeted incremental detailing (not just volume) may be needed to defend share rather than just chase growth.
> 
> 4. **Midwest is closest to target (97.7%) with strong ROI (2.63)** — steady-state effort, low priority for reallocation.
> 
> **Caveat**: I don't have HCP-segment-level effect data (that agent returned zero results), so this reallocation is regional, not segment-targeted. If you want to prioritize *within* a region (e.g., West), I'd recommend using severity-tier or therapy-line breakdowns as a proxy, since HCP-segment splits aren't available in the current data.


---

## Session `n2`

### 2.1 — T3 · PASS
**Q:** Build a patient cohort for Remibrutinib CSU with inclusion criteria for adults over 18 diagnosed in 2024
*ttfb 20.121599999999997s · first_progress 20.1214s · total 20.1333s · tools: clinical_context_tool*

> I should be upfront about what this tool suite can and can't do here: this is a commercial analytics platform (KPIs, causal drivers, market access) — it does not have patient-level EHR/registry data, so I can't literally construct a clinical trial-style patient cohort with inclusion/exclusion logic (e.g., pulling actual patient records matching "age >18 AND diagnosis date in 2024"). Let me pull what I *can* ground this in: Remibrutinib's real FDA-label/clinical context, plus the real segmentation axes available in the commercial data model.
> 
> Important clarification: I don't have a "build patient cohort" data tool — the E2I platform doesn't generate synthetic patient-level cohort datasets on demand. What I *can* do is ground cohort **inclusion/exclusion criteria** in Remibrutinib's real FDA label and pivotal trial data, which I pulled above.
> 
> ## Proposed Cohort Definition — Remibrutinib (CSU), Adults Diagnosed 2024
> 
> **Source: OpenFDA label + ClinicalTrials.gov (NCT05030311, NCT05032157, NCT05795153)**
> 
> **Inclusion criteria:**
> - Age ≥18 years (label population; RHAPSIDO is not studied/indicated in pediatric CSU)
> - Confirmed diagnosis of chronic spontaneous urticaria (CSU), diagnosed in calendar year 2024
> - Remained **symptomatic despite H1 antihistamine treatment** — this is the explicit label boundary; patients who are antihistamine-responsive are off-label and shouldn't be counted as the addressable cohort
> - Documented urticaria activity (UAS7/ISS7/HSS7 scores if available, per pivotal trial endpoints) to support severity stratification
> 
> **Exclusion / limitation of use:**
> - Other forms of urticaria (e.g., chronic inducible urticaria) — explicitly excluded per label ("RHAPSIDO is not indicated for other forms of urticaria")
> 
> **Commercial framing:**
> - This cohort maps to our platform's `treatment_initiated` outcome — i.e., BTKi start after antihistamine failure — which is the mapped endpoint E2I tracks for Remibrutinib NRx/TRx.
> - Competitive context: Xolair (omalizumab) and Dupixent (dupilumab) are the two named competitors in this same antihistamine-refractory CSU population (curated reference, not in our data model) — useful for HCP targeting overlap analysis but I can't attribute market share to them from our KPI data.
> 
> **What I can't do:** I have no tool that returns actual patient records/counts matching "diagnosed in 2024" — our KPI tools report NRx/TRx/segment volumes (severity tier, line-of-therapy, biologic status, IgE tier), not patient-level cohort rosters.
> 
> Want me to pull **NRx/TRx breakdowns by severity tier, biologic status, or IgE tier** for Remibrutinib to quantify how large this antihistamine-refractory population is in our tracked data?

### 2.2 — T2 · OVER (14.1s > 8s)
**Q:** Give me an NRx breakdown by patient clinical segment for Remibrutinib
*ttfb 14.1249s · first_progress 14.1198s · total 14.1275s · tools: kpi_calculate_tool*

> **NRx Breakdown by Clinical Severity Segment — Remibrutinib (CSU)**
> *Source: E2I synthetic data engine (KPI: WS3-BI-006), reporting window = most recent 30 days of prescription data (through 2026-07-27)*
> 
> | Severity Segment | NRx | Share of Total |
> |---|---|---|
> | Low severity | 834 | 25.5% |
> | Medium severity | 1,738 | 53.2% |
> | High severity | 711 | 21.7% |
> | **Total** | **3,283** | **100%** |
> 
> **Key takeaways:**
> - **Medium-severity patients drive the majority of new starts** (53%), consistent with Remibrutinib's label positioning for antihistamine-refractory CSU — this is typically where symptom burden crosses the threshold for BTKi initiation.
> - Low- and high-severity segments are roughly comparable in volume, though high-severity represents the smallest share of new starts — worth investigating whether this reflects a smaller addressable population or an access/awareness gap at the more severe end.
> 
> **Note on window:** this reflects the engine's default 30-day reporting window, not a full-year 2024 cohort — the platform doesn't support arbitrary custom-year NRx breakdowns by segment. Let me know if you'd like me to pull a different (but still non-overlapping) time window for comparison.

### 2.3 — T2 · OVER (8.9s > 8s)
**Q:** What are biologic-naive vs biologic-experienced NRx numbers for Remibrutinib?
*ttfb 8.9048s · first_progress 8.9001s · total 8.9071s · tools: kpi_calculate_tool*

> **NRx by Biologic Status — Remibrutinib (CSU)**
> *Source: E2I synthetic data engine (KPI: WS3-BI-006), reporting window = most recent 30 days of prescription data (through 2026-07-27)*
> 
> | Biologic Status | NRx | Share |
> |---|---|---|
> | Biologic-naive | 1,937 | 59.0% |
> | Biologic-experienced | 1,346 | 41.0% |
> | **Total** | **3,283** | **100%** |
> 
> **Key takeaway:** Biologic-naive patients account for the majority (59%) of new Remibrutinib starts, suggesting it's being used both as an earlier-line option for antihistamine-refractory CSU and as a switch/add-on for patients who've already tried a biologic (e.g., omalizumab) — the latter representing a meaningful 41% share worth tracking for switch-dynamics analysis.
> 
> Note: this covers the engine's default 30-day window, not the 2024 cohort discussed earlier — the platform doesn't support arbitrary custom-year breakdowns by biologic status. Let me know if you'd like this compared against a prior 30-day period for trend direction.

### 2.4 — T3 · PASS
**Q:** What is driving the drop in Remibrutinib NRx in the northeast region this quarter?
*ttfb 15.8016s · first_progress 4.910100000000001s · total 15.8682s · tools: causal_analysis_tool*

> **Important caveat first:** I don't have a region-filtered NRx trend for the Northeast, and the trigger query returned results across all brands (not filtered cleanly to Remibrutinib/Northeast) with no volume or "drop" metric attached — so I can't confirm a Northeast-specific NRx decline exists in the data, let alone quantify it. I can only speak to the *general* causal drivers of Remibrutinib NRx.
> 
> **Causal drivers of Remibrutinib NRx (national, not region-specific)**
> *Source: causal_analysis_tool, KPI = NRx, brand = Remibrutinib*
> 
> | Cause | Effect Size | Confidence | Lag | Est. Business Impact |
> |---|---|---|---|---|
> | Treatment initiated → NRx (via patient onboarding) | 0.41 | 81.6% | 73 days | $72,247 |
> | Intent to prescribe → NRx (via new patient starts) | 0.27 | 81.6% | 68 days | $111,256 |
> | Sample dropped → NRx (via trial experience) | 0.092 | 84.1% | 87 days | $30,580 |
> 
> **Relevant triggers touching Remibrutinib HCPs (last 90 days, unfiltered by region):**
> - A **critical-priority "competitive_threat"** trigger (confidence 0.74) flagged recent competitive detailing at one HCP — this is the most direct signal of competitive displacement risk, though it's tied to a Kisqali HCP record, not confirmed Northeast/Remibrutinib.
> - Several **prescription_opportunity** triggers tied to "high prescriber fit + treatment gap" show mixed rep response — one was **rejected** and flagged as a false positive, another had a negative outcome delta (-0.106), suggesting some targeting/model drift.
> - Multiple **cross_sell** triggers (patient profile matches additional indication) for Remibrutinib show decent acceptance but no completed outcome tracking yet.
> 
> **Bottom line:** the strongest documented national drivers of NRx softness are slippage in "intent to prescribe" conversion and reduced sample/trial experience feeding into fewer patient starts — both with ~2-3 month lags, meaning a dip this quarter likely traces back to lower HCP engagement/detailing activity in Q1. However, I cannot confirm this is Northeast-specific or quantify a regional drop without a region-filtered NRx trend, which this query didn't return.
> 
> Would you like me to run a `kpi_calculate_tool` NRx pull with `region: Northeast` to at least establish whether a decline is actually present before we lean further into causal attribution?

### 2.5 — T3 · PASS
**Q:** Where are the biggest untapped opportunities to grow Remibrutinib market share?
*ttfb 19.398400000000002s · first_progress 5.426399999999999s · total 19.4045s · tools: kpi_calculate_tool*

> ## Untapped Growth Opportunities — Remibrutinib TRx Share
> 
> *Source: kpi_calculate_tool (WS3-BI-008), causal_analysis_tool, and e2i_data_query_tool (recommendations) — reporting window = most recent 30 days of prescription data (through 2026-07-27), except regional figures pulled from episodic records dated 2026-07-01/06-01*
> 
> **Current position:** Remibrutinib holds **33.2% TRx share** of the tracked portfolio (Fabhalta + Kisqali + Remibrutinib) — this is portfolio share, not share vs. external competitors like Xolair/Dupixent, which aren't in the data model.
> 
> ### 1. Regional gaps — biggest concrete opportunity
> | Region | Metric | Value vs Target | Achievement |
> |---|---|---|---|
> | **Northeast** | market_share | 0.25 vs 0.28 target | 89.3% |
> | **Northeast** | hcp_engagement_score | 10.0 vs 14.65 target | **68.3%** — largest gap of any metric shown |
> | **South** | NRx | 13,972 vs 18,971 target | 73.6% — largest NRx shortfall |
> | **West** | TRx | 49,585 vs 72,315 target | 68.6% — largest TRx shortfall |
> 
> **Northeast HCP engagement (68.3% of target) is the standout underperformer** — and it directly matters because of the causal driver below.
> 
> ### 2. Causal levers ranked by confidence/impact
> | Driver | Effect on TRx share/volume | Confidence | Lag | Est. Impact |
> |---|---|---|---|---|
> | Rep detailing frequency → TRx volume (via HCP engagement) | +0.298 | 89.7% | 86 days | $91,289 |
> | Formulary status → TRx volume (via patient access) | +0.272 | 82.3% | 26 days | $91,457 |
> | Persistent 180d → TRx volume (via refill continuity) | +0.301 | 83.6% | 68 days | $66,695 |
> | HCP coverage → TRx market share (via prescriber base) | +0.114 | 83.3% | 67 days | $50,167 |
> | Copay support program → TRx volume (via adherence) | +0.132 | 80.3% | 68 days | $58,702 |
> | Competitor activity → TRx market share (via share of voice) | **-0.058** | 88.5% | 56 days | -$19,668 |
> 
> ### Bottom line — where to focus
> 1. **Northeast: close the HCP engagement gap.** It's the single weakest KPI (68.3% of target) and directly maps to the strongest causal lever (rep detailing → engagement → volume, $91K impact, 90% confidence). This is the highest-conviction opportunity.
> 2. **South: NRx underperformance (73.6% of target)** — worth pairing with copay support and formulary-access pushes, both high-confidence volume drivers with fast (26-day) turnaround for formulary fixes.
> 3. **West: TRx shortfall (68.6%)** despite strong ROI (2.94) — suggests untapped volume upside if engagement/access levers are pulled here too, not a productivity problem.
> 4. **Defensive note:** competitor share-of-voice is the only negative driver identified (-$19.7K impact) — worth monitoring in regions where detailing gaps coincide with competitive activity (e.g., Northeast).
> 
> **Bottom line:** the biggest lever isn't a new region-of-focus discovery — it's that Northeast is simultaneously the weakest-engagement region *and* sits on the highest-confidence causal path (detailing → engagement → volume), making it the priority for incremental rep activity/detailing investment.

### 2.6 — T3 · PASS
**Q:** How can I optimize resource allocation for Remibrutinib in the northeast region?
*ttfb 15.674s · first_progress 6.7414s · total 15.678799999999999s · tools: orchestrator_tool*

> **Resource allocation optimization for Remibrutinib — Northeast: no formal optimization model available**
> 
> I tried running a formal resource-allocation optimization (rep/detailing/investment prioritization) through the orchestrator, and it **failed closed** rather than fabricate numbers: the platform doesn't have per-entity allocation/response data (rep-activity rows, response coefficients, or a defined budget constraint) needed to solve a real allocation problem for Remibrutinib in the Northeast. No values were invented.
> 
> **What I can offer instead — grounded in the data already pulled in this conversation:**
> 
> Based on the causal drivers and regional gaps identified earlier for Remibrutinib:
> 
> | Priority | Rationale | Data point |
> |---|---|---|
> | **1. HCP engagement in Northeast** | Largest gap of any tracked metric — direct causal link to TRx via rep detailing frequency (+0.298 effect, 89.7% confidence, ~86-day lag) | Northeast HCP engagement at **68.3% of target** (10.0 vs 14.65) |
> | **2. Northeast market share** | Below target, tied to engagement gap | 0.25 vs 0.28 target (89.3% achievement) |
> | **3. Formulary/access support** | Faster-acting lever (26-day lag) with strong effect (+0.272) on TRx volume via patient access | From causal driver table (national) |
> | **4. Persistency/refill support programs** | High-confidence lever (83.6%) on TRx volume via refill continuity (+0.301) | From causal driver table (national) |
> 
> **Directional recommendation:** Since detailing frequency → HCP engagement → TRx share is the strongest causal chain and Northeast engagement is the weakest KPI in the region, prioritize incremental rep time/detailing investment there before broader spend, and pair it with formulary/access support (faster payoff, ~26 days) to compound the effect. But this is a qualitative prioritization based on existing causal/regional data — not a quantified optimal allocation (e.g., "X reps to Y territories") because that requires the per-entity allocation inputs the tool flagged as missing.
> 
> If you can supply territory-level rep counts, costs, and expected response rates, I can route those through the resource_optimizer for an actual constrained-optimization solution.

### 2.7 — T2 · OVER (9.0s > 8s)
**Q:** What is the intent-to-prescribe delta for Remibrutinib?
*ttfb 8.9502s · first_progress 3.9223000000000003s · total 8.9532s · tools: kpi_calculate_tool*

> **Intent-to-Prescribe Δ — Remibrutinib**
> *Source: kpi_calculate_tool (KPI BR-002, "Remi - Intent-to-Prescribe Δ"), engine's default reporting window (no specific period requested/applied)*
> 
> - **Value: 1.007** (status: **good**)
> 
> This means intent-to-prescribe signals are up slightly (~+0.7%) relative to the baseline the engine tracks internally — a modestly positive trend, not a decline. Note this uses the platform's default window rather than a specific quarter or month, since none was applied here.
> 
> For context, in the earlier causal analysis, "Intent to prescribe → NRx" was one of the strongest national drivers of NRx (effect 0.27, 81.6% confidence, ~68-day lag) — so this slightly positive delta is a modestly encouraging signal for near-term NRx, though it doesn't isolate Northeast specifically.


---

## Session `n3`

### 3.1 — T2 · OVER (11.6s > 8s)
**Q:** What percentage of PNH patients have been tested?
*ttfb 11.562s · first_progress 11.5574s · total 11.5652s · tools: clinical_context_tool*

> I don't have a "testing rate" KPI available for Fabhalta (PNH) — the query returned zero records, meaning this metric isn't tracked in the data model.
> 
> What I can tell you:
> - **No testing-rate data exists** in our commercial analytics for Fabhalta. This system tracks commercial/prescribing KPIs (TRx, NRx, NBRx, market share, conversion rates) — not diagnostic testing or screening rates for PNH (e.g., flow cytometry testing prevalence among suspected patients).
> - For actual PNH testing/diagnosis rates, you'd need epidemiological or diagnostic-testing data sources (e.g., lab claims data, published epidemiology studies), which aren't part of this tool's data model.
> 
> If you're interested in a related, available metric — such as Fabhalta's **conversion rate** (testing/diagnosis → treatment initiation proxy, since our mapped endpoint for Fabhalta is "treatment initiation") — I can pull that instead. Would that be useful?

### 3.2 — T2 · PASS
**Q:** What is the current TRx volume for Fabhalta?
*ttfb 5.031899999999999s · first_progress 5.0296s · total 5.0335s · tools: kpi_calculate_tool*

> **Fabhalta TRx volume: 15,370 prescriptions**
> 
> - Source: KPI registry WS3-BI-005 (Total Prescriptions), synthetic data source
> - Window: this reflects the engine's default reporting window — the **most recent 30 days**, with data through **2026-07-27** — not a custom period you specified
> 
> Let me know if you'd like this broken down by severity tier, line of therapy, or region, or trended over time.

### 3.3 — T3 · PASS
**Q:** Predict which HCP segments are most likely to increase Fabhalta prescriptions next quarter
*ttfb 17.2591s · first_progress 15.4583s · total 17.267799999999998s · tools: e2i_data_query_tool*

> Note: there's no dedicated "HCP segment propensity/next-quarter prediction" model in the data — no forward-looking predictions were returned for Fabhalta. What follows is a **causal-driver-based inference**, not a formal forecast, using the regional performance snapshot (data through 2026-07-01/07-17) and Fabhalta's TRx causal chains (confidence ≥0.5).
> 
> **Regions/segments most likely to drive TRx growth next quarter, based on current causal drivers:**
> 
> | Region | Signal | Why it points to growth |
> |---|---|---|
> | **West** | NRx +42.3% YoY (6,953.5 vs target 9,252.96); highest ROI (2.74) | Strong new-patient momentum + best conversion efficiency — leading indicator of TRx growth |
> | **Midwest** | Conversion rate 0.31 (96.9% of target), ROI 1.68 | Near-target conversion with efficient spend — stable, reliable growth candidate |
> | **South** | TRx +17.1% YoY already; conversion +8.8% YoY | Existing volume momentum, though market share is flattest (-0.7% YoY) — growth is volume-driven, not share-driven |
> | **Northeast** | Conversion rate 0.37 (highest), but HCP engagement only 72.3% of target | Highest conversion once engaged — upside if engagement gap closes |
> 
> **Top causal levers explaining *why* segments would move (Fabhalta, min confidence 0.5):**
> - **Formulary status → TRx volume** (effect size 0.329, confidence 0.81, ~22-day lag) — largest business impact (~$129K est.) — HCPs in favorably-formularied regions/plans are the strongest bet
> - **Persistent 180-day adherence → TRx volume** (effect 0.292, confidence 0.80) — HCPs with high-persistence patient panels
> - **Rep detailing frequency → TRx via HCP engagement** (effect 0.134, confidence 0.89, ~29-day lag) — segments with engagement scores below target (Northeast, South) have the most headroom from increased detailing
> - **HCP coverage → market share via prescriber base** (effect 0.182, confidence 0.92, ~63-day lag)
> 
> **Bottom line — segments to prioritize:**
> 1. **West-region HCPs** — ride the NRx surge with continued engagement
> 2. **Northeast HCPs with formulary access but low engagement** — biggest untapped conversion upside; close the engagement-to-target gap (currently 72.3%)
> 3. **Midwest, high-persistence panels** — steady, high-ROI segment for continued investment
> 
> *Source: Fabhalta episodic KPI records (regional, monthly snapshots through 2026-07) + causal_analysis_tool registry (synthetic data, 6 causal paths, confidence 0.5+). This is directional inference from correlational/causal signals, not a validated predictive model — treat as a prioritization hypothesis for HCP targeting, not a guaranteed forecast.*

### 3.4 — T3-T4 · OVER (75.2s > 40s)
**Q:** Design an experiment to measure whether speaker programs increase Fabhalta NRx
*ttfb 75.1478s · first_progress 71.9327s · total 75.1525s · tools: orchestrator_tool*

> Note: the automated **experiment_designer agent timed out** and returned no output — so I'll design this directly, grounded in the causal drivers actually returned for Fabhalta NRx (min confidence 0.5, synthetic data source).
> 
> ## Experiment: Do Speaker Programs Increase Fabhalta NRx?
> 
> **Relevant causal context (Fabhalta NRx drivers, current data):**
> | Path | Effect size | Confidence | Lag |
> |---|---|---|---|
> | Intent-to-prescribe → new patient starts → NRx | 0.336 | 0.766 | 43 days |
> | Treatment initiated → patient onboarding → NRx | 0.24 | 0.917 | 30 days |
> | Sample dropped → trial experience → NRx | 0.074 | 0.808 | 18 days |
> 
> Speaker programs plausibly act on **intent-to-prescribe** (the largest, though lower-confidence, lever) — so the design should track that pathway with a ~43-day lag before expecting NRx movement.
> 
> **Design:**
> 1. **Unit of randomization:** HCP (not patient), stratified by region and current NRx decile to balance baseline volume.
> 2. **Arms:** Treatment (invited/attended a Fabhalta speaker program) vs. matched control (no invitation, similar specialty/region/baseline NRx).
> 3. **Primary outcome:** NRx volume per HCP, measured over a 60–90 day post-program window (covers the 43-day intent-to-prescribe lag plus buffer).
> 4. **Secondary/mediator outcomes:** intent-to-prescribe survey or proxy (e.g., new patient starts), to test whether the hypothesized causal pathway actually mediates the effect.
> 5. **Method:** Difference-in-differences comparing pre/post NRx trend between attendee and control HCPs, or propensity-score matching if randomization isn't feasible (self-selection into attendance is a known confound).
> 6. **Minimum detectable effect:** Size the sample so you can detect an NRx lift on the order of the causal chain's effect size (~0.24–0.34 standardized effect) with reasonable power (80%, α=0.05).
> 7. **Guardrail:** Since "sample_dropped" also has a positive path to NRx (effect 0.074, confidence 0.808, 18-day lag), control for sample-drop activity so it doesn't confound the speaker-program effect.
> 
> **Caveat:** No dedicated experiment-design tool output was available (agent timeout), so this is a manually constructed design using the causal registry above rather than a system-generated protocol. Want me to retry the orchestrator call for a fuller automated design?

### 3.5 — T5 · n/a
**Q:** What did the digital twin simulation say about expected lift and sample size?
*ttfb 6.639s · first_progress 6.6384s · total 12.6836s · tools: e2i_data_query_tool*

> I need to be direct: **no digital twin simulation exists in the data for this** — I haven't run one, and there's no tool output referencing "digital twin," "expected lift," or "sample size" for speaker programs on Fabhalta NRx anywhere in what I've retrieved.
> 
> To be clear about what happened:
> - My previous experiment design was **manually constructed** from causal chain effect sizes (0.24–0.34) — I did not run a simulation, and I did not report a sample-size calculation.
> - I have not called a simulation tool, because none of the available tools (predictions, experiments, orchestrator) has returned digital-twin-style output for this question.
> 
> Let me actually check the predictions/experiments data stores before assuming there's nothing there.
> 
> There's no digital twin simulation output for this — both queries (predictions and experiments) returned only regional NRx/TRx/market-share performance snapshots for Fabhalta (data through 2026-06-01/07-01), not simulation results with expected lift or sample-size estimates.
> 
> **What's missing:**
> - No expected-lift figure for a speaker-program intervention
> - No simulated/recommended sample size
> - No digital-twin agent output at all — the tool results are the same regional actuals-vs-target data (e.g., West NRx 6,953.5 vs target 9,252.96, ROI 2.74; Northeast NRx 8,158.02 vs target 11,262.53, ROI 2.34) already surfaced earlier in this conversation, not a forward simulation.
> 
> **Bottom line:** This system doesn't have a digital twin/simulation capability that produced lift or sample-size estimates for the speaker-program experiment — that part of the design (step 6 in my earlier answer, the ~0.24–0.34 effect-size-based MDE) was my own statistical estimate from the causal chain data, not a simulation output. If you want, I can refine that sample-size estimate using standard power-calculation assumptions (baseline NRx variance, desired power/alpha) — just confirm you want that math walked through.

### 3.6 — T3 · OVER (81.4s > 40s)
**Q:** Design an experiment to test whether increasing rep visits improves Fabhalta adoption
*ttfb 81.3011s · first_progress 4.9692s · total 81.356s · tools: causal_analysis_tool*

> Note: the orchestrator's `experiment_designer` agent again returned no substantive output ("no significant performance gaps identified" — a gap-analysis fallback, not an experiment design). So I'll build this directly from the actual causal chains returned for **Fabhalta treatment_initiated** (min confidence 0.5, synthetic data source).
> 
> ## Experiment: Does Increasing Rep Visits Improve Fabhalta Adoption (Treatment Initiation)?
> 
> **Relevant causal evidence found:**
> 
> | Path | Effect size | Confidence | Lag | Business impact |
> |---|---|---|---|---|
> | Treatment arm → **treatment_initiated** (via disease_severity) | 0.235 | 0.94 | 9 days | ~$68,825 |
> | Treatment arm → discontinued_180d (via engagement_score, prior_therapy) | 0.226 | 0.943 | 41 days | ~$32,003 |
> 
> Note: neither path directly names "rep visits" as the cause — the registry's `cause` variable is `treatment_arm`, mediated by disease_severity (for initiation) or engagement_score/prior_therapy (for discontinuation). Rep-visit frequency is a plausible upstream driver of `engagement_score`, but the data doesn't give a direct rep-visit → adoption effect size, so treat this as directional guidance, not a validated causal estimate for rep visits specifically.
> 
> **Design:**
> 1. **Unit of randomization:** HCP, stratified by disease-severity mix of panel and baseline engagement score (the two mediators identified above).
> 2. **Arms:** Increased rep-visit cadence (e.g., +1 visit/month) vs. current cadence (control), balanced by region.
> 3. **Primary outcome:** Treatment-initiation rate per HCP panel, measured over a **~9–14 day** window post-visit-increase (matches the 9-day lag on the initiation path).
> 4. **Secondary/guardrail outcome:** 180-day discontinuation rate, tracked out to **41 days** post-visit-change and beyond — since higher engagement also has a measurable path to discontinuation (0.226 effect, 0.943 confidence), more visits could plausibly cut both ways; this guards against an initiation win masking a persistence loss.
> 5. **Mediator tracking:** Capture disease_severity mix and engagement_score directly, so you can test whether the effect actually flows through the hypothesized mediators (not just visit count).
> 6. **Method:** Difference-in-differences (pre/post initiation rate, treatment vs. control HCPs) or propensity-matched comparison if random assignment of rep cadence isn't operationally feasible.
> 7. **Sample size:** No simulation or power-calculation tool output exists for this — sizing should be done manually against the 0.235 effect size at your desired power/alpha, which I can walk through if useful.
> 
> **Bottom line:** The data supports rep-driven engagement as a plausible lever on adoption, but only via an indirect chain (engagement_score/disease_severity) — no tool has produced a direct rep-visit effect size or a validated experiment design. Want me to run the manual sample-size math for the 0.235 effect size?


---

## Session `n4`

### 4.1 — T3 · PASS
**Q:** Create a cohort of HCPs who are oncologists in the northeast
*ttfb 21.88s · first_progress 18.319s · total 21.8949s · tools: e2i_data_query_tool*

> I can't build an actual named-HCP roster from what's available — there's no individual-HCP directory/CRM tool in this system, only **aggregated, regional KPI data**. Here's what I can honestly offer:
> 
> **What the system returned:**
> - Routing: `agent_routing_tool` recommends this task go to the **heterogeneous_optimizer** (primary) with **cohort_constructor** (secondary) — confidence 0.76 — these are the right agents to define a target segment and materialize an HCP list, but that materialization step isn't exposed to me as a callable tool here.
> - Regional data pulled was for **Kisqali, Northeast region** (most recent snapshots: 2026-06-01 and 2026-07-01):
>   - TRx: 252,475 (93.6% of target, +28.3% YoY)
>   - NRx: 71,965 (101.3% of target, +41.4% YoY)
>   - Market/TRx share: 0.49 (target 0.57, 86.0% achievement)
>   - Conversion rate: 0.55 (target 0.73)
>   - HCP engagement score: 10.0 (target 16.47, 60.7% achievement)
> 
> **Important caveat:** this is regional/brand-level performance data, not a list of individual oncologists with names, NPIs, or contact details — the tools I have access to don't expose an HCP-level directory or specialty tag ("oncologist") to filter on. I can't fabricate a roster.
> 
> **What I'd suggest instead:**
> - If your CRM/MDM (e.g., Veeva, IQVIA OneKey) has an oncology-specialty + Northeast-region filter, that's the correct source for the actual HCP list.
> - I can help define the **targeting criteria/segment logic** (e.g., low engagement score + high conversion-rate gap = high-priority Northeast oncology cohort) for your CRM team to execute, or pull deeper causal drivers behind the Northeast engagement shortfall (60.7% of target) if useful.
> 
> Want me to run a causal analysis on why Northeast HCP engagement is underperforming target, to help prioritize which oncologists to target first?

### 4.2 — T3 · PASS
**Q:** Build a cohort of high-value HCPs who prescribed more than 50 TRx last quarter
*ttfb 10.8708s · first_progress 10.8706s · total 10.8736s · tools: none*

> I need to be upfront: I don't have access to an individual-HCP-level data tool — everything available to me (`e2i_data_query_tool`, `kpi_calculate_tool`, `causal_analysis_tool`, etc.) works at the **brand/region/segment aggregate level** (business_metrics, causal registry, treatment_events aggregates). There's no HCP directory, NPI list, or prescriber-level roster exposed to me, so I cannot produce an actual list of named HCPs who wrote >50 TRx last quarter — doing so would mean fabricating data, which I won't do.
> 
> What I *can* do honestly with these tools:
> 
> - **Aggregate TRx for last quarter** by brand (via `kpi_calculate_tool` with a quarter window)
> - **Segment-level breakdowns** (severity tier, line-of-therapy, region, and for Remibrutinib: biologic status/IgE tier) — showing which segments concentrate volume, as a proxy for where high-value prescribing clusters
> - **Causal drivers** of TRx volume, to explain what's associated with high-prescribing behavior
> 
> That's useful for *targeting logic* (e.g., "high-TRx segments are X, Y, Z — prioritize HCPs in those segments/regions"), but it's not a prescriber-level cohort with names/NPIs.
> 
> **My recommendation:** the actual >50-TRx-per-HCP cohort needs to be built from your CRM/data warehouse (Veeva, IQVIA) at the prescriber grain — I can help define the selection logic/criteria for that pull.
> 
> In the meantime, would you like me to:
> 1. Pull last quarter's TRx by brand/region/segment to identify which segments are driving high volume (a data-grounded proxy), or
> 2. Run causal analysis on what drives high TRx, to inform your CRM-side HCP selection criteria?
> 
> Let me know which brand(s)/quarter you want, and which of the two above is useful.

### 4.3 — T4 · PASS
**Q:** Segment HCPs by prescription volume into high, medium, and low tiers
*ttfb 9.0472s · first_progress 9.046700000000001s · total 9.0518s · tools: none*

> Same limitation applies here as with the previous asks — I don't have an HCP-level prescriber dataset (no NPI/prescriber grain tool). Everything I can query is aggregated at brand/region/patient-segment level, so I can't tier individual HCPs by their prescription volume without fabricating data.
> 
> **What's actually available and comparable:**
> The data model does support **patient-level segmentation** (severity tier: low/medium/high; line-of-therapy 0–3; region; and for Remibrutinib, biologic status/IgE tier) with real TRx/NRx/NBRx volumes per bucket. That's a legitimate "high/medium/low volume tier" breakdown — just of patient segments, not HCPs.
> 
> If that's a useful proxy, I can, for example:
> - Pull TRx by severity tier (low/medium/high_severity) for a brand — showing which patient segment concentrates volume
> - Pull TRx by line-of-therapy for the same purpose
> 
> **For true HCP-level tiering (high/medium/low prescriber volume), you'd need:**
> - Your CRM/data warehouse (Veeva, IQVIA OneKey) pulled at the prescriber (NPI) grain
> - I can help define the tiering logic/thresholds (e.g., >50 TRx = high, 20–50 = medium, <20 = low) for that pull, and the heterogeneous_optimizer/cohort_constructor agents (per routing) are the right components to operationalize it once real HCP-level data is available.
> 
> Would you like me to run the **patient-segment volume breakdown** (by severity/LOT) for a specific brand and quarter as a data-grounded proxy, or just draft the **HCP tiering criteria/thresholds** for your CRM team to execute?

### 4.4 — T3 · PASS
**Q:** Which HCP segments show the strongest treatment effect for Remibrutinib?
*ttfb 15.0345s · first_progress 14.9398s · total 15.0385s · tools: causal_analysis_tool*

> Another important clarification: the same limitation applies here — this isn't an "HCP segment" question the data can actually answer at the prescriber level, but the causal registry does surface **patient-level heterogeneity** in treatment effect for Remibrutinib, and that's a legitimate (if different) answer.
> 
> **What the causal analysis actually shows (Remibrutinib, causal registry data, no specific time window applied):**
> 
> Two distinct causal pathways for `treatment_arm → outcome`, both mediated by patient-level factors — not HCP segments:
> 
> | Effect | Mediating Path | Effect Size | Confidence | Est. Business Impact |
> |---|---|---|---|---|
> | Treatment initiated | via **disease_severity** | 0.437 | 94.5% | ~$182,579 |
> | Persistent at 180 days | via **engagement_score + disease_severity** | 0.493 | 94.4% | ~$158,005 |
> 
> **Interpretation:** the strongest treatment effect heterogeneity is driven by **disease severity** and **patient engagement score** — not by HCP-level segments. Patients with higher disease severity show a larger treatment-initiation effect (0.437), and the combination of higher engagement + severity drives the strongest 180-day persistence effect (0.493, the largest of the two).
> 
> **On HCP segments specifically:** I queried the `heterogeneous_optimizer` agent (the one designed to detect subgroup/heterogeneous treatment effects) directly for Remibrutinib and it returned **zero analyses on file** — there's no HCP-segment-level heterogeneous-effect output currently stored for this brand.
> 
> **Bottom line:** the data can tell you *which patient characteristics* (severity, engagement) most amplify Remibrutinib's treatment effect — useful for prioritizing which patient profiles to target — but it cannot currently tell you which **HCP segments** show the strongest effect; that agent analysis doesn't exist yet for this brand.
> 
> Want me to pull the **TRx/NRx breakdown by severity tier** for Remibrutinib to see where volume concentrates among the higher-effect (high-severity) segment?

### 4.5 — T2 · OVER (17.7s > 8s)
**Q:** What is our trigger precision and acceptance rate this month?
*ttfb 17.6372s · first_progress 9.8294s · total 17.6964s · tools: e2i_data_query_tool*

> **Trigger precision and acceptance rate — last 30 days (all brands, engine's reporting window ≈2026-06-29 to present):**
> 
> There's no pre-computed KPI metric on file for either "trigger_precision" or "acceptance_rate" — both `kpi` queries returned **zero records**. So I can't give you the platform's official rolled-up figures for this month.
> 
> What I *can* do is compute proxies from the 10 raw triggers returned in this window:
> 
> **Acceptance rate (from raw trigger records, n=10):**
> | Status | Count |
> |---|---|
> | accepted | 4 |
> | overridden | 2 |
> | rejected | 1 |
> | pending | 3 |
> 
> → Acceptance rate ≈ **4/10 = 40%** (pending ones haven't resolved yet, so this may shift)
> 
> **Precision proxy (false-positive flag, n=10):**
> - 1 of 10 triggers flagged `false_positive_flag: true` → implied precision ≈ **90%** (9/10), though only a handful have `outcome_tracked: true`, so this is a rough, small-sample estimate — not a validated precision metric.
> 
> **Caveat:** These are derived from a small raw sample (10 triggers) across Kisqali, Remibrutinib, and Fabhalta combined, not an official aggregated KPI — treat as directional only. No non-overlapping prior-period figure was returned, so I can't tell you whether this represents a trend change from last month.
> 
> Want me to break this down by brand, or check if a longer window (e.g., last 90 days) has enough volume for a more reliable acceptance/precision estimate?

### 4.6 — T2 · OVER (52.2s > 8s)
**Q:** What is the false alert rate and override rate for triggers?
*ttfb 51.9185s · first_progress 2.9703000000000004s · total 52.2086s · tools: e2i_data_query_tool*

> **False alert rate & override rate — triggers, last 90 days (all brands combined, engine's reporting window, n=100 raw trigger records, capped by query limit — actual total trigger volume may be larger):**
> 
> **False positive rate (from `false_positive_flag`):**
> - 17 of 100 triggers flagged `false_positive_flag: true` → **false alert rate ≈ 17%**
> 
> **Override rate (from `acceptance_status`):**
> 
> | Status | Count | % of 100 |
> |---|---|---|
> | Accepted | 55 | 55% |
> | Pending | 21 | 21% |
> | Rejected | 13 | 13% |
> | **Overridden** | **8** | **8%** |
> | Expired | 3 | 3% |
> 
> - **Override rate ≈ 8%** of all triggers (8/100)
> - If you exclude still-unresolved (`pending`) triggers and look only at resolved ones (79 total: accepted+overridden+rejected+expired), override rate ≈ **10.1%** (8/79)
> 
> **Caveats:**
> - This is a raw sample of 100 trigger records across Kisqali, Remibrutinib, and Fabhalta combined (not brand-split), pulled from the engine's "last 90 days" window — consistent with what you asked for.
> - No prior non-overlapping 90-day period was returned by the tool, so I can't tell you whether 17% false-alert / 8% override represents an improvement or decline vs. an earlier quarter — that would need a separate non-overlapping pull (e.g., the 90 days before this window).
> - These are proxy metrics from raw trigger records, not a validated/pre-aggregated KPI (no `trigger_precision`/`acceptance_rate` KPI records exist on file, consistent with what I found last time).
> 
> Want me to split this false-alert/override breakdown by brand, or pull the prior 90-day window (non-overlapping) for a real trend comparison?

### 4.7 — T3 · PASS
**Q:** Did rep actions driven by triggers actually lift prescriptions?
*ttfb 15.7968s · first_progress 5.0516000000000005s · total 15.896600000000001s · tools: causal_analysis_tool*

> **Did rep-driven trigger actions lift prescriptions? — causal registry (all brands, no time window applied) + raw trigger sample (n=50, `outcome_tracked=true` filter)**
> 
> **Yes — the causal registry directly supports this**, via the `rep_detailing_frequency → trx_volume` pathway (mediated by HCP engagement), which is the closest analog to "rep actions from triggers":
> 
> | Brand | Effect Size | Confidence | Lag (days) | Est. Business Impact |
> |---|---|---|---|---|
> | Remibrutinib | 0.298 | 89.7% | 86 | ~$91,289 |
> | Fabhalta | 0.134 | 88.7% | 29 | ~$42,707 |
> | Kisqali | 0.166 | 79.6% | 77 | ~$38,244 |
> 
> **Interpretation:** higher rep detailing frequency causally lifts TRx volume across all three brands, with high confidence (~80–90%) and a lag of 1–3 months before the effect shows up. Remibrutinib shows the strongest effect and highest dollar impact.
> 
> **Supporting evidence from tracked trigger outcomes (n=17 of 50 sampled triggers with `outcome_tracked=true`):**
> - Triggers that were **accepted and acted on** (e.g., `scvtrg_00059` — accepted, action "sent_info," `conversion_flag: true`, outcome_value 0.744; `scvtrg_14508` — accepted, `conversion_flag: true`, outcome 0.554) show positive conversion and above-zero outcome values.
> - Triggers that were **rejected, overridden, or had no action taken** mostly show `outcome_value: 0.0` and `conversion_flag: false` (e.g., `scvtrg_00088` rejected → outcome 0.0; `scvtrg_00105` overridden → outcome 0.0; `scvtrg_00128` accepted but no action taken → outcome 0.0).
> - Pattern: accepted-and-acted triggers cluster toward positive outcomes/conversions; rejected/overridden/no-action triggers cluster at zero — directionally consistent with the causal path above, though this is a small sample (17 outcome-tracked records) and not a formal treatment-effect estimate isolating "acted-on" vs. "not acted-on" as a controlled comparison.
> 
> **Bottom line:** Yes — rep detailing frequency (the mechanism behind trigger-driven rep actions) has a statistically supported, positive causal effect on TRx volume for all three brands (highest for Remibrutinib), and the raw trigger sample is directionally consistent with that finding.
> 
> **Caveat:** No non-overlapping prior-period comparison was pulled here — this is a causal effect estimate, not a before/after trend. Want me to isolate a formal accepted-vs-rejected outcome comparison (matched sample) for one brand to sharpen this?


---

## Session `n5`

### 5.1 — T2-T3 · PASS
**Q:** What is the current system health score?
*ttfb 5.8514s · first_progress 5.8488s · total 5.8614s · tools: e2i_data_query_tool*

> I queried the agent system for a "health_score" analysis, but no data was returned (0 records found) — this specific metric isn't currently available in the system for the "health_score" agent name.
> 
> This could mean:
> - System health scoring isn't tracked under this agent identifier
> - The data isn't populated for this query type yet
> 
> If you're looking for the status of the 21-agent architecture instead, I can check agent routing/status directly — let me know if you'd like me to pull that.

### 5.2 — T1 · OVER (8.1s > 3s)
**Q:** What agents are available in the system?
*ttfb 8.0616s · first_progress 8.0589s · total 8.0656s · tools: agent_routing_tool*

> The routing tool didn't return a full agent directory — it just routed your query itself, to the **health_score** agent (with **explainer** as a secondary agent for formatting), at 98% routing confidence via the DSPy routing method.
> 
> So I can't give you the complete list of all 21 agents from this call. What I can tell you about the architecture generally:
> - It's a **21-agent tiered system** covering areas like KPI analysis, causal analysis, health scoring, explanation/formatting, recommendations, and orchestration.
> - This particular query got routed to **health_score** (primary) + **explainer** (secondary).
> 
> If you'd like, I can query specific agent categories individually (e.g., causal, recommendation, KPI agents) to build out a fuller inventory — let me know.

### 5.3 — T2 · OVER (9.9s > 8s)
**Q:** What is the ROC-AUC and calibration of the current Kisqali model?
*ttfb 9.9076s · first_progress 9.848s · total 9.911299999999999s · tools: e2i_data_query_tool*

> I checked both drift/model-quality reports and prediction records for Kisqali, and neither contains ROC-AUC or calibration metrics. The results returned are KPI performance records (market share, TRx, conversion rate, HCP engagement) by region for 2026-06/07 — not model-performance statistics.
> 
> **Bottom line: ROC-AUC and calibration for the Kisqali model aren't available in the data returned by these tools.** This system doesn't appear to expose model-level classification metrics (ROC-AUC, calibration curves) through the `drift_reports` or `predictions` query types — those are populated with commercial KPI values instead.
> 
> If you're looking for model performance monitoring specifically, I'd need a dedicated model-ops/ML-monitoring data source, which isn't part of my current toolset. Let me know if you'd like me to search the document knowledge base for any model validation reports that might reference this.

### 5.4 — T3 · PASS
**Q:** Is there any feature drift in the Kisqali model?
*ttfb 9.9661s · first_progress 9.9617s · total 9.9688s · tools: e2i_data_query_tool*

> No feature-drift data was returned for Kisqali (last 30 days). The query for `drift_reports` on Kisqali came back with 10 records, but none of them are actual model feature-drift metrics — they're all commercial KPI events (hcp_engagement_score, market_share, conversion_rate by region for 2026-06/07) and a gap-analysis summary.
> 
> **Bottom line:** There is no evidence of feature drift in the data available — but that's because this data source doesn't track feature-level drift statistics for the Kisqali model at all, not because drift was measured and found absent. As noted earlier, this system's `drift_reports` query type appears to return commercial KPI records rather than ML model-monitoring metrics (ROC-AUC, PSI, feature distribution shifts, etc.).
> 
> If you need true feature-drift monitoring, that would require a dedicated model-ops/ML-monitoring source, which isn't part of my current toolset. I can search the document knowledge base for any model validation/drift reports if that would help.

### 5.5 — T3 · PASS
**Q:** Why did the model flag this HCP segment - what features drove the prediction?
*ttfb 11.2449s · first_progress 11.244399999999999s · total 12.8448s · tools: e2i_data_query_tool*

> I don't have enough specificity to pull the exact prediction you're referring to — you haven't named a brand or which HCP segment was flagged. Since our conversation has been focused on Kisqali, let me check what's available there for HCP-related predictions/recommendations to see if I can surface something relevant.
> 
> Neither query returned model-level feature importance or SHAP-style prediction drivers for a specific HCP segment. Both `predictions` and `recommendations` calls for Kisqali came back with the same 10 commercial KPI records (market_share, hcp_engagement_score, TRx, conversion_rate) by region for June–July 2026 — not per-HCP-segment prediction outputs or feature attributions.
> 
> **Bottom line:** There's no data source here that exposes "why the model flagged this segment" at the feature level (e.g., prescribing velocity, HCP specialty, engagement recency, claims mix). This system's `predictions` and `recommendations` query types return aggregated regional KPI performance, not model explainability output (no SHAP values, feature weights, or segment-flag rationale).
> 
> What I *can* do instead:
> - Pull the closest proxy — regional performance patterns that might correlate with why a segment stands out (e.g., **west** and **northeast** show the lowest hcp_engagement_score achievement, 66.9% and 60.7% of target respectively, which could be the kind of signal a targeting model would key off of)
> - Search the document knowledge base for any model documentation or scoring methodology writeups that describe the HCP segmentation model's inputs
> 
> Would you like me to try either of those, or is there a specific HCP segment/ID you have in mind that I should search for directly?

### 5.6 — T1 · OVER (14.5s > 3s)
**Q:** Explain what heterogeneous treatment effects mean in our analyses
*ttfb 14.522200000000002s · first_progress 10.3438s · total 14.528s · tools: document_retrieval_tool*

> **Heterogeneous Treatment Effects (HTE)** in our system refer to CATE (Conditional Average Treatment Effect) analysis, run by the **heterogeneous_optimizer** agent. Rather than assuming an intervention (e.g., an HCP engagement tactic, marketing touch, or treatment protocol) has the same effect on everyone, CATE analysis estimates how the effect *varies* across different HCP or patient subgroups.
> 
> From the episodic records retrieved (dated June 2026, not brand-specific in the metadata), the analyses report:
> - **Heterogeneity score**: a measure of how much the treatment effect varies across the population (values seen: 0.10, 0.11, 0.29 — higher = more variation in response)
> - **High responders**: subgroups where the intervention had an outsized positive effect (counts ranged 0–4 across runs)
> - **Low responders**: subgroups where the intervention had little/no effect (counts ranged 2–5 across runs)
> 
> **In practice, this means:** instead of a single "average" effect size for a campaign or trigger, the model segments the population into those who respond strongly vs. weakly — which is what powers targeting recommendations (e.g., prioritize HCP segments flagged as "high responders" for a given intervention, and deprioritize or redesign outreach for "low responders").
> 
> **Caveat on this data:** the retrieved records don't specify which brand or which specific intervention each CATE run corresponds to (brand field is null in the metadata), and heterogeneity/responder counts fluctuate run-to-run (e.g., 0.11→0.29) without an explanation of what changed — so I can't attribute a specific HTE finding to Kisqali, Fabhalta, or Remibrutinib from this data alone.
> 
> If you want, I can search for CATE analyses tied specifically to a named brand or intervention (e.g., the Remibrutinib email campaign failure noted in the same pull) to see if heterogeneity data exists for that specific case.

### 5.7 — T3 · PASS
**Q:** How confident are we in the rep-visit effect - did it pass refutation tests?
*ttfb 15.210799999999999s · first_progress 3.6823s · total 15.2164s · tools: causal_analysis_tool*

> **Short answer: I have confidence scores for the rep-visit → outcome causal paths, but no data on whether they passed formal refutation tests (placebo tests, random common cause, etc.).**
> 
> The `causal_analysis_tool` and `e2i_data_query_tool` both returned the same 12/10 causal paths for "rep visit" (i.e., `rep_detailing_high` / `rep_detailing_frequency`) across all three brands, no specific period stated (registry-level, not time-windowed). Confidence values are model-fit confidence (via `backdoor.linear_regression`), not refutation-test pass/fail flags:
> 
> | Brand | Cause → Effect | Confidence | Effect Size | Lag (days) | Business Impact |
> |---|---|---|---|---|---|
> | Kisqali | rep_detailing_high → treatment_initiated | 0.93 | 0.043 | 8 | $6,432 |
> | Remibrutinib | rep_detailing_frequency → roi (via trx_volume) | 0.909 | 0.073 | 21 | $7,426 |
> | Remibrutinib | rep_detailing_frequency → trx_volume (via hcp_engagement) | 0.897 | 0.298 | 86 | $91,289 |
> | Fabhalta | rep_detailing_frequency → trx_volume (via hcp_engagement) | 0.887 | 0.134 | 29 | $42,707 |
> | Fabhalta | rep_detailing_frequency → intent_to_prescribe (via message_recall) | 0.879 | 0.230 | 35 | $40,738 |
> | Remibrutinib | rep_detailing_frequency → intent_to_prescribe (via message_recall) | 0.865 | 0.292 | 54 | $89,972 |
> | Fabhalta | rep_detailing_high → treatment_initiated | 0.861 | 0.055 | 45 | $23,285 |
> | Kisqali | rep_detailing_frequency → roi (via trx_volume) | 0.851 | 0.198 | 40 | $59,581 |
> | Remibrutinib | rep_detailing_high → treatment_initiated | 0.840 | 0.033 | 54 | $10,907 |
> | Fabhalta | rep_detailing_frequency → roi (via trx_volume) | 0.815 | 0.052 | 81 | $13,402 |
> | Kisqali | rep_detailing_frequency → trx_volume (via hcp_engagement) | 0.796 | 0.166 | 77 | $38,244 |
> | Kisqali | rep_detailing_frequency → intent_to_prescribe (via message_recall) | 0.772 | 0.267 | 35 | $119,357 |
> 
> **What this means for "confidence":**
> - All 12 paths report confidence between **0.77–0.93**, method `backdoor.linear_regression` — these are association-strength/model-fit scores, not outputs of a refutation test suite.
> - Neither tool result includes any refutation-test fields (e.g., placebo-treatment, random-common-cause, data-subset robustness checks, or pass/fail flags) — that metadata isn't present in this data source.
> 
> **Bottom line:** I can't confirm whether the rep-visit effect passed formal causal refutation tests — that information isn't exposed by `causal_analysis_tool` or `e2i_data_query_tool`. If refutation testing is done elsewhere (e.g., a causal-inference model-validation log), I'd need to search the document knowledge base for it — let me know if you'd like me to try that.


---

## Session `n6`

### 6.1 — T4 · PASS
**Q:** Compare TRx market share for Kisqali vs its competitors over the last 6 months, explain what's driving the difference, and recommend where to focus reps next quarter
*ttfb 22.869s · first_progress 19.9485s · total 22.8735s · tools: kpi_calculate_tool*

> ## Kisqali TRx Share — Last 6 Months (Jan 29 – Jul 29, 2026)
> 
> **Important clarification on "competitors":** the data model only tracks Novartis's own portfolio (Kisqali, Fabhalta, Remibrutinib) — it does **not** include external competitors like Ibrance (palbociclib) or Verzenio (abemaciclib). So the "TRx Share" figure below is Kisqali's share of the *tracked Novartis portfolio's* prescriptions, not a head-to-head vs. named CDK4/6 competitors. I can't attribute the remaining share to Ibrance/Verzenio from this data — that would require external market-data the system doesn't have.
> 
> - **Kisqali TRx Share: 31.0%** of tracked portfolio prescriptions (window applied: 2026-01-29 to 2026-07-29, as requested)
> - Regional detail (Jul 2026 snapshot): South 43% (target 48%, 89.6% attainment), West 47% (target 50%, 94% attainment), Northeast 49% (target 57%, 86% attainment) — Northeast has the largest absolute gap to target.
> 
> ## What's Driving It (causal analysis, confidence ≥0.79)
> 
> | Driver | Effect on share/volume | Confidence | Lag |
> |---|---|---|---|
> | **HCP coverage** → prescriber base | +0.09 on TRx share | 0.899 | 55 days |
> | **Persistence (180d)** → refill continuity | +0.285 on TRx volume | 0.892 | 24 days |
> | **Formulary status** → patient access | +0.223 on TRx volume | 0.805 | 78 days |
> | **Rep detailing frequency** → HCP engagement | +0.166 on TRx volume | 0.796 | 77 days |
> | **Copay support program** → adherence | +0.088 on TRx volume | 0.794 | 64 days |
> | **Competitor activity** → share of voice | **-0.073 on TRx share** | 0.793 | 70 days |
> 
> **Takeaway:** Coverage breadth and patient persistence/access are the strongest positive levers (highest effect sizes and business impact: $127.5K for persistence, $100.7K for formulary access). Competitor share-of-voice is the one negative driver identified, pulling share down modestly — but note "competitor" here refers to the causal-registry construct, not a named external brand.
> 
> Also notable: HCP engagement scores are running well below target across all regions (60-79% of target) despite positive YoY growth, suggesting engagement capacity — not demand — is the binding constraint right now.
> 
> ## Recommendations for Next Quarter
> 
> 1. **Prioritize Northeast** — lowest attainment (86%) and lowest HCP engagement achievement (60.7% of target), despite the highest ROI on engagement (1.44). Biggest headroom for incremental reps.
> 2. **Expand HCP coverage/prescriber base first** — highest-confidence lever (0.899) with a relatively fast 55-day lag; directly targets the #1 driver of TRx share.
> 3. **Reinforce persistence and access programs** (copay support, formulary navigation) alongside detailing — these carry the largest dollar impact ($127.5K and $100.7K respectively) even though their lag is longer (64-78 days), so start now for Q4 payoff.
> 4. **South region** has the highest YoY TRx growth (+30%) and strong ROI (2.89) — a good candidate for sustaining investment rather than new reps, since it's already outperforming.
> 
> *Sources: `kpi_calculate_tool` (TRx Share, synthetic KPI engine), `causal_analysis_tool` (causal registry, synthetic), `e2i_data_query_tool` (episodic memory/regional recommendations), `clinical_context_tool` (OpenFDA/ChEMBL/ClinicalTrials.gov — real label/MOA data, competitor list is curated reference only).*
> 
> Want me to pull a regional TRx trend chart to visualize where Northeast is lagging?

### 6.2 — T4 · PASS
**Q:** Which regions are underperforming on Remibrutinib conversion rate, and for those regions, what would be the ROI of shifting 20% more rep capacity there?
*ttfb 19.5362s · first_progress 11.9692s · total 19.543200000000002s · tools: kpi_calculate_tool*

> ## Remibrutinib Conversion Rate by Region (July 2026)
> 
> **Note on data source:** the direct `kpi_calculate_tool` doesn't support combining brand + region for conversion rate, so region-level figures below come from the recommendations/episodic-memory data source (July 1, 2026 snapshot). The brand-only conversion rate (no region split) is **63.4%** as of 2026-07-27, but that figure isn't region-decomposable via the calculator — it's a different aggregation than the region rows below, so don't treat them as reconcilable.
> 
> | Region | Conversion Rate | Target | Achievement | ROI |
> |---|---|---|---|---|
> | **South** | 33% | 43% | **76.7%** ⚠️ | 1.29 |
> | **Midwest** | 36% | 40% | **90.0%** ⚠️ | 1.20 |
> | West | 43% | 41% | 104.9% ✅ | 1.64 |
> | Northeast | 49% | 49% | 100.0% ✅ | 1.67 |
> 
> **Underperforming regions: South and Midwest** — both missing target, with South the larger gap (10.3 pts below target) and also the lowest ROI (1.29) of all four regions.
> 
> ## Estimated ROI of Shifting 20% More Rep Capacity
> 
> The tool results don't include a capacity-elasticity model (i.e., no data on how conversion rate responds to a % change in rep capacity), so I can't calculate a precise incremental ROI for a 20% capacity shift — that would require a causal/elasticity figure not present in these results, and I don't want to fabricate one.
> 
> What I *can* say directionally from the ROI figures already reported:
> - **South** currently returns **1.29 ROI** at its current rep allocation — if capacity is added at a similar marginal return, incremental spend there would need to close a 10-point achievement gap to be worthwhile; it's the weakest ROI of the four regions, so a 20% capacity shift here is a lower-confidence bet unless paired with a driver fix (e.g., access/formulary issues depressing conversion).
> - **Midwest** at **1.20 ROI** is the lowest of the four — even less efficient on current spend, so shifting capacity here without addressing why conversion is 90% of target risks diminishing returns.
> 
> **Recommendation:** Before committing incremental rep capacity, I'd suggest running a `causal_analysis_tool` pass on South and Midwest specifically to identify what's suppressing conversion (formulary, HCP coverage gaps, competitor activity, etc.) — that would let us model expected ROI of a capacity shift rather than assume the current blended ROI holds at the margin. Want me to pull that causal breakdown next?

### 6.3 — T4 · PASS
**Q:** If conversion rate in the west is below 15%, which patient segments should we prioritize?
*ttfb 5.6507s · first_progress 5.6501s · total 5.656899999999999s · tools: none*

> West region conversion rate is currently **43%** (target 41%, 104.9% achievement) — it is **not** below 15%, so that condition doesn't apply. West is actually one of the two outperforming regions (along with Northeast), not underperforming.
> 
> Since the premise isn't met, I won't fabricate a segment-prioritization answer for a hypothetical threshold that doesn't reflect the real data. If you'd like, I can instead:
> 
> - Pull the actual **conversion rate by patient segment** (low/medium/high severity) or **by line-of-therapy** for Remibrutinib in the West region to see if any sub-segment there is underperforming even though the regional blend looks healthy, or
> - Revisit the two regions that **are** actually underperforming — **South** (33%, 76.7% of target) and **Midwest** (36%, 90% of target) — and break those down by segment/therapy-line to find where to prioritize.
> 
> Which would be more useful?

### 6.4 — T4 · PASS
**Q:** Give me a launch-readiness snapshot for Fabhalta: % PNH tested, NRx trend, top adoption barriers, and one experiment we should run next
*ttfb 23.932299999999998s · first_progress 7.724s · total 23.9957s · tools: clinical_context_tool*

> ## Fabhalta Launch-Readiness Snapshot
> 
> **% PNH tested:** Not available in this data model — there's no PNH-testing-rate metric in the tool results (the platform tracks prescribing/access/engagement KPIs, not diagnostic testing rates). I won't fabricate a figure; if this is tracked elsewhere (e.g., lab-partner or diagnostics data), it isn't surfaced here.
> 
> **NRx Trend (Fabhalta, last 6 months: Jan 29 – Jul 29, 2026):**
> - Total NRx: **3,610** new prescriptions
> - ⚠️ Coverage warning on this figure: *"91% of this 181-day total falls in its most recent 30 days — the data is not evenly distributed across the window. Do NOT treat the full-window figure as a baseline for the recent period; compare against a prior non-overlapping window instead."* I don't have a valid non-overlapping prior-period NRx figure in these results, so I can't characterize this as accelerating/decelerating — just that recent activity (trailing 30 days = 3,289) dominates the total.
> - Regional TRx (Jul 1, 2026 snapshot, YoY): Northeast 42,226 (+27.6%), South 33,303 (+17.1%), Midwest 30,804 (+30.6%), West 40,744 (+26.1%, 108.8% of target — the only region beating target). All four regions show strong double-digit YoY growth, consistent with early-launch ramp.
> 
> **Top Adoption Barriers (from causal drivers + regional gaps):**
> 1. **HCP engagement below target** — Northeast HCP engagement score 10.0 vs. target 13.83 (72.3% attainment), the weakest attainment metric in the dataset — suggests reps aren't reaching sufficient depth/frequency with prescribers.
> 2. **Market share underperformance in South/West/Midwest** — South 13% share (target 15%, 86.7%), West 14% (target 16%, 87.5%), Midwest 13% (target 14%, 92.9%) — only Northeast is near target (17% vs 18%, 94.4%). Since Fabhalta's causal drivers show **treatment initiation → patient onboarding** as the strongest lever (effect +0.24 on NRx, confidence 0.917, $41.4K impact), the share gaps likely reflect onboarding/access friction rather than demand.
> 3. **Sample/trial-experience drag** — "sample_dropped" → trial_experience has a *positive* effect size (+0.074, confidence 0.808) on NRx — meaning dropped samples correlate with volume in the causal registry, an unusual signal worth investigating (could indicate samples are being converted to paid scripts, or a data artifact) rather than a straightforward barrier.
> 4. Given Fabhalta's REMS/boxed-warning requirement (serious infection risk from encapsulated bacteria, mandatory vaccination counseling) — an FDA-label fact — this administrative burden is a plausible on-the-ground adoption friction point for HCPs unfamiliar with complement-inhibitor REMS protocols, though this isn't directly quantified in the KPI data.
> 
> **Recommended Experiment for Next Quarter:**
> Run an **A/B test on rep detailing intensity targeting HCP engagement in Northeast** (lowest engagement attainment, 72.3%) paired with a **REMS-onboarding support intervention** (e.g., streamlined vaccination-coordination toolkit for new starts) — measuring impact on **treatment_initiated → NRx** (the highest-confidence causal path, 0.917, $41.4K estimated impact). Since "intent_to_prescribe → new_patient_starts" also shows a strong effect size (+0.336, confidence 0.766, $69.4K impact), a secondary test arm could target intent-to-prescribe conversion in South/West/Midwest where share is furthest below target.
> 
> *Sources: kpi_calculate_tool (NRx), causal_analysis_tool (NRx drivers), episodic-memory regional snapshots (Jul 1, 2026), clinical_context_tool (FDA label/REMS, ClinicalTrials.gov).*

### 6.5 — T4 · PASS
**Q:** Forecast Kisqali TRx volume for the next two quarters and tell me the biggest risk to that forecast
*ttfb 4.865399999999999s · first_progress 4.8647s · total 16.914099999999998s · tools: causal_analysis_tool*

> I don't have a forecasting tool with real predictive modeling for TRx volume in my available toolset that I've verified works for this — let me check the predictions data source before answering, rather than extrapolating a number myself.
> 
> ## Kisqali TRx Forecast — Next Two Quarters
> 
> **Important caveat:** The tools don't return a true forward-looking forecast model for Kisqali TRx — no query returned projected future values with confidence intervals. What I have is the most recent snapshot data (Jun–Jul 2026, both months identical) and causal drivers, which I'll use to characterize the trajectory directionally rather than fabricate a precise two-quarter number.
> 
> **Latest regional TRx (Jun/Jul 2026 snapshot):**
> | Region | TRx | Target | Achievement | YoY |
> |---|---|---|---|---|
> | Northeast | 252,475 | 269,839 | 93.6% | +28.3% |
> | South | 203,508 | 215,586 | 94.4% | +30.0% |
> | Midwest | 213,916 | 219,011 | 97.7% | +17.9% |
> | West | 160,203 | 231,136 | **69.3%** | +25.1% |
> 
> Combined tracked-region TRx ≈ **830,100/month**, running at ~89% of target overall, with strong YoY growth (+17.9% to +30.0%) across all four regions. If that YoY growth rate holds, next two quarters would likely continue an upward trend — but I don't have a validated forecast engine output to give you a specific number, so treat this as directional, not a forecast figure.
> 
> ## Biggest Risk to the Forecast
> 
> **HCP engagement is the standout risk.** Every region is stuck at exactly **10.0** on HCP engagement score, missing target badly:
> - Northeast: 10.0 vs 16.47 target (**60.7%** achievement — worst)
> - West: 10.0 vs 14.95 target (66.9%)
> - South: 10.0 vs 13.21 target (75.7%)
> 
> This matters causally: **rep detailing frequency → HCP engagement → TRx volume** is a confirmed driver (effect +0.166, confidence 0.796, $38.2K business impact), and **HCP coverage → prescriber base → TRx market share** is the single strongest driver in the registry (confidence 0.899, effect +0.09 on share). With engagement flat/depressed across all regions, the mechanism that sustains volume growth is under-fueled — if it doesn't improve, the current YoY growth trend is at risk of decelerating, especially in West, which is already the weakest region (69.3% achievement).
> 
> Secondary risk: **competitor activity → share-of-voice** is the one confirmed negative driver on TRx share (effect −0.073, confidence 0.793), which could erode the market-share component of the forecast even if absolute volume keeps growing.
> 
> **Bottom line:** the biggest threat isn't demand — it's that flat, below-target HCP engagement in every region could cap the rep-driven upside baked into the current growth trajectory, particularly in West.


---

## Session `a1`

### A.1 — T6 · n/a
**Q:** Hello, how are you?
*ttfb 4.5687s · first_progress 4.5684s · total 4.5744s · tools: none*

> I'm doing well, thank you for asking! I'm the E2I Analytics Assistant, ready to help you with pharmaceutical commercial analytics for our three brands:
> 
> - **Kisqali** (HR+/HER2- breast cancer)
> - **Fabhalta** (PNH)
> - **Remibrutinib** (CSU)
> 
> I can help you with things like:
> - **KPI analysis** — TRx, NRx, NBRx, market share, conversion rates
> - **Causal insights** — what's driving changes in your metrics
> - **Recommendations** — HCP targeting and market access strategies
> - **Clinical/label context** — indications, mechanism of action, competitive landscape
> - **Trend charts** — visualize KPI performance over time
> 
> What would you like to dig into today?


---

## Session `a2`

### A.2a — T6 · n/a
**Q:** What can you do?
*ttfb 9.4055s · first_progress 9.4052s · total 9.408700000000001s · tools: none*

> I'm the E2I Analytics Assistant, built to support commercial analytics for three Novartis brands: **Kisqali** (HR+/HER2- breast cancer), **Fabhalta** (PNH), and **Remibrutinib** (CSU). Here's what I can help you with:
> 
> **1. KPI Analysis & Computation**
> - Calculate real values for TRx, NRx, NBRx, TRx market share, conversion rate, ROI, and HCP coverage
> - Break these down by patient severity tier, line of therapy, region, and (for Remibrutinib specifically) biologic status or IgE tier
> - Support custom time windows ("last 3 months," "Q1 2025," specific date ranges)
> - Render inline trend charts (line charts over time, with optional segment/line-of-therapy comparisons)
> 
> **2. Causal Analysis**
> - Identify modeled cause-effect drivers behind outcomes like TRx, conversion, treatment initiation, and persistence
> - Report confidence levels and methods (e.g., DoWhy/EconML) behind each causal chain
> 
> **3. Clinical/Regulatory Grounding**
> - Pull real FDA-label indications, mechanism of action, pivotal trial endpoints, real-world evidence, and competitor landscape for each brand — to ground commercial strategy (not for individualized medical/prescribing advice)
> 
> **4. Agent System Insights**
> - Explain and route queries through the 21-agent tiered architecture (data prep, causal impact, drift monitoring, experiment design, predictions, recommendations, etc.)
> 
> **5. Recommendations, Triggers & Predictions**
> - Surface AI-generated recommendations, alert triggers/explanations for metric changes, ML predictions, and drift reports
> 
> **6. Knowledge Base Search**
> - Retrieve relevant documents, historical patterns, and experiment results via hybrid RAG search
> 
> **7. Multi-Agent / Complex Queries**
> - Handle multi-part questions (e.g., "compare TRx across brands and explain the causal factors") by decomposing them and orchestrating multiple tools/agents
> 
> What would you like to explore first — a specific KPI, a brand deep-dive, or a causal question?

### A.2b — T6 · n/a
**Q:** What KPIs are available for Kisqali?
*ttfb 9.5562s · first_progress 3.0717s · total 9.561200000000001s · tools: e2i_data_query_tool*

> Based on the latest data pull (reporting month **July 2026**, regional rollups), Kisqali tracks these KPI types:
> 
> **Core Volume/Performance KPIs**
> - **TRx** (Total Prescriptions) — e.g., West: 160,203; Northeast: 252,475; South: 203,508; Midwest: 213,916
> - **NRx** (New Prescriptions) — e.g., West: 61,280; Northeast: 71,965; South: 60,476; Midwest: 47,866
> - **Market Share (TRx Share)** — ranges 0.42–0.49 across regions
> - **Conversion Rate** — ranges 0.51–0.67 across regions
> 
> **Engagement/Access KPI**
> - **HCP Engagement Score** — ~10.0 across regions (vs. targets of 12.6–16.5)
> 
> **Per-HCP Rollup Metrics** (individual HCP-level granularity)
> - `trx_count`, `nrx_count`, `total_rx_count`, `market_share`, `conversion_rate` per HCP
> 
> Each metric also carries **target, achievement rate, YoY/MoM change, ROI, statistical significance, and confidence intervals** — so you can assess not just the value but performance vs. goal and trend direction.
> 
> **Available breakdown axes**: region (northeast, south, west, midwest shown), severity tier, and line of therapy. Note: biologic status and IgE tier are Remibrutinib-only and not applicable to Kisqali.
> 
> Want me to compute a specific KPI (e.g., overall TRx or market share) for a particular time window or breakdown?


---

## Session `a3`

### A.3 — T6 · n/a
**Q:** Waht is the TRx for Kisqali?
*ttfb 5.649100000000001s · first_progress 5.6467s · total 5.650600000000001s · tools: kpi_calculate_tool*

> **Kisqali TRx: 13,242 total prescriptions**
> 
> - Source: `WS3-BI-005` (synthetic data)
> - Window: This reflects the engine's default reporting window — the **most recent 30 days** of prescription data (through 2026-07-27), not a specific period request.
> 
> Let me know if you'd like this broken down by patient segment, line of therapy, or region, or charted over time.


---

## Session `a4`

### A.4 — T6 · n/a
**Q:** Show me converson rate for Remibrutnib
*ttfb 5.057s · first_progress 5.0534s · total 5.0585s · tools: kpi_calculate_tool*

> **Remibrutinib Conversion Rate: 63.4%** (status: good)
> 
> - **Source:** WS3-BI-009, synthetic data
> - **Window:** No specific period was requested from the tool's default — this reflects the engine's standard reporting window (most recent 30 days of trigger data), with data through 2026-07-27
> 
> Let me know if you'd like this broken down by patient segment (severity), line of therapy, or region.


---

## Session `a5`

### A.5 — T6 · n/a
**Q:** Why did it drop?
*ttfb 4.696899999999999s · first_progress 4.6965s · total 4.6983999999999995s · tools: none*

> I want to give you a precise, data-backed answer, but I don't have enough context yet to know what "it" refers to. Could you clarify:
> 
> - **Which metric** dropped (e.g., TRx, NRx, NBRx, market share, conversion rate)?
> - **Which brand** (Kisqali, Fabhalta, or Remibrutinib)?
> - **Which time period/region** you're looking at?
> 
> Once I have that, I can pull the causal drivers and trigger/alert data to explain the drop with actual analysis rather than guessing.


---

## Session `a6`

### A.6 — T6 · n/a
**Q:** What is TRx?
*ttfb 9.1582s · first_progress 9.1578s · total 9.162600000000001s · tools: none*

> **TRx (Total Prescriptions)** is a core pharmaceutical commercial KPI representing the **total volume of prescriptions dispensed** for a drug within a given period — it includes:
> 
> - **New prescriptions (NRx)** — first-time scripts for a patient on that brand
> - **Refill/continuing prescriptions** — repeat scripts for patients already on therapy
> 
> **Key points:**
> - TRx = NRx + Refills, so it captures overall prescribing volume/demand, not just new patient starts.
> - It's commonly tracked at brand, region, HCP-segment, or severity-tier level to gauge market performance and prescriber behavior.
> - In the E2I data model, **TRx Share** measures a brand's share of prescriptions *within the tracked portfolio* (Kisqali, Fabhalta, Remibrutinib) — not versus external competitors like Xolair or Dupixent, since those aren't in the data model.
> - Related KPIs: **NRx** (new prescriptions only) and **NBRx** (new-to-brand Rx, i.e., first-ever prescription of that brand for a patient) help distinguish overall volume from new-patient acquisition trends.
> 
> Would you like me to pull the current TRx value (or trend) for a specific brand like Kisqali, Fabhalta, or Remibrutinib?


---

## Session `a8`

### A.8-cold — T2 · PASS
**Q:** What is TRx for Kisqali?
*ttfb 4.8683000000000005s · first_progress 4.865600000000001s · total 4.8697s · tools: kpi_calculate_tool*

> **Kisqali TRx: 13,242 total prescriptions**
> 
> - **Source**: WS3-BI-005 (synthetic data)
> - **Window**: Reflects the engine's default reporting window — the most recent 30 days of prescription data, as of 2026-07-27
> 
> Let me know if you'd like this broken down by patient segment, therapy line, or region.

### A.8-warm — T5 · n/a
**Q:** What is TRx for Kisqali?
*ttfb 6.1819s · first_progress 6.1667s · total 6.2292s · tools: kpi_calculate_tool*

> **Kisqali TRx: 13,242 total prescriptions**
> 
> - **Source**: WS3-BI-005 (synthetic data)
> - **Window**: Same as before — this reflects the engine's default reporting window (most recent 30 days), as of 2026-07-27, not a newly specified period
> 
> Let me know if you'd like this broken down by patient segment, therapy line, or region.


---

## Session `a9`

### A.9-seed — T3 · PASS
**Q:** Why did Kisqali TRx drop in Q1 in the northeast region?
*ttfb 15.2462s · first_progress 6.5546999999999995s · total 15.251700000000001s · tools: causal_analysis_tool*

> Kisqali TRx in the Northeast held flat at **142** for both Q1 2025 (Jan–Mar 2025) and Q4 2024 (Oct–Dec 2024) — so at the quarterly level there's no drop; the two periods reconcile exactly.
> 
> That said, the **trailing 30-day** figures embedded in each window do show softening: 52 TRx (36.6% share of the quarter) in the most recent 30 days of Q1 vs. 57 TRx (40.1% share) in the most recent 30 days of Q4 — a modest late-quarter deceleration, though this isn't a valid apples-to-apples baseline comparison (different quarters' trailing windows), just a within-quarter signal.
> 
> **Likely causal drivers** (from the causal engine, Kisqali/Northeast, confidence ≥0.79):
> - **Competitor activity → share of voice → TRx market share**: effect size **-0.073**, confidence 0.793, ~**-$24.2K** business impact — the only negative driver identified, consistent with the "competitive_threat" trigger flagged for a Northeast HCP (recent competitive detailing detected, 0.737 confidence).
> - Positive/protective drivers that may have partially offset decline: persistent 180-day refill continuity (+0.285 effect on volume), formulary/patient access (+0.223), rep detailing frequency (+0.166), HCP coverage/prescriber base (+0.09 on share), and copay support (+0.088).
> 
> **Bottom line**: There's no quarter-over-quarter TRx drop in the topline number (142 → 142), but competitive encroachment is the one statistically significant negative force in the Northeast, and the trailing-30-day share slipped from ~40% to ~37% of quarterly volume — worth monitoring as a potential early signal.
> 
> Would you like me to pull the specific HCPs/accounts driving that competitive-threat trigger for targeted follow-up?

### A.9-followup — T5 · n/a
**Q:** Why is this happening?
*ttfb 13.9775s · first_progress 3.8647s · total 13.9831s · tools: e2i_data_query_tool*

> Here's the mechanism behind the Northeast trailing-30-day softening for **Kisqali**:
> 
> **Root cause: competitive encroachment**
> - The causal engine identifies **competitor_activity → share_of_voice → TRx market share** as the single negative driver in the model (effect size **-0.073**, confidence **0.793**, ~**-$24.2K** estimated business impact, ~70-day lag).
> - This is corroborated by an active **trigger** on a specific Northeast HCP (`scvhcp_03716`, patient `scvpt_000038`): a **critical-priority "competitive_threat"** flagged 2026-07-21, confidence **0.737**, reason = *"Recent competitive detailing detected."* Notably, this trigger's status is **"overridden"** — meaning it was delivered to CRM but the recommended action ("Prioritize relationship-building activities") was not accepted/acted on, so the threat likely went unaddressed.
> 
> **Why it hasn't shown up as a bigger topline drop**
> Several positive forces are actively offsetting the competitive pressure in the same causal model:
> | Driver | Effect size | Confidence | Est. impact |
> |---|---|---|---|
> | Refill continuity (180-day persistence) | +0.285 | 0.892 | +$127.5K |
> | Formulary/patient access | +0.223 | 0.805 | +$100.7K |
> | Rep detailing frequency | +0.166 | 0.796 | +$38.2K |
> | HCP coverage/prescriber base | +0.09 | 0.899 | +$29.5K |
> | Copay support program | +0.088 | 0.794 | +$17.0K |
> 
> These are all larger in magnitude than the competitive drag, which is why quarterly TRx held flat (142 → 142) even as the trailing-30-day trend softened (57→52 units, 40.1%→36.6% of-quarter share).
> 
> **Bottom line**: The softening is being driven by a competitor gaining share of voice via increased detailing — concretely evidenced by an overridden competitive-threat alert on at least one Northeast HCP — while retention/access/engagement drivers are currently strong enough to keep the quarterly number stable. If that overridden trigger and similar ones aren't acted on, the erosion could compound next quarter.
> 
> Want me to pull the full list of HCPs with open/overridden competitive-threat triggers in the Northeast so reps can prioritize follow-up?


---

## Session `a10`

### A.10 — T6 · n/a
**Q:** Our Kisqali TRx dropped in the northeast last quarter while conversion rates for Remibrutinib stayed flat, and I need to understand several things: what actually caused the Kisqali decline, whether biologic-experienced patient segments were disproportionately affected compared to biologic-naive ones, what the models predict for both brands next quarter, whether any data drift could be confounding these reads, and finally what experiment we should run to test whether adding rep capacity in the northeast would recover the trend.
*ttfb 45.7353s · first_progress 10.9151s · total 45.8486s · tools: causal_analysis_tool*

> Here's what the data actually shows — note two of the requested figures **could not be computed** because the tool couldn't parse "last quarter" (it needs an explicit window like "last 3 months" or "Q1 2025 to Q1 2025"), so I'm reporting from the causal registry and the engine's latest monthly snapshot (dated 2026-07-01) instead.
> 
> ## 1. What caused the Kisqali Northeast TRx decline
> From `causal_analysis_tool` (Kisqali, Northeast, last_90_days, 6 paths, conf ≥0.5), ranked by business impact:
> 
> | Cause | Effect (via) | Effect size | Confidence | Lag | Est. $ impact |
> |---|---|---|---|---|---|
> | Refill discontinuation (persistent_180d↓) | TRx volume (refill continuity) | 0.285 | 0.892 | 24d | $127,512 |
> | Formulary status | TRx volume (patient access) | 0.223 | 0.805 | 78d | $100,658 |
> | Rep detailing frequency↓ | TRx volume (HCP engagement) | 0.166 | 0.796 | 77d | $38,244 |
> | HCP coverage | Market share (prescriber base) | 0.090 | 0.899 | 55d | $29,541 |
> | Copay support program | TRx volume (adherence) | 0.088 | 0.794 | 64d | $17,025 |
> | **Competitor activity** | Market share (share of voice) | **–0.073** | 0.793 | 70d | **–$24,218** |
> 
> Supporting snapshot: Northeast Kisqali **market share 0.49 vs 0.57 target (86% achievement)**, **conversion rate 0.55 vs 0.73 target (75.3%)**, and **HCP engagement score 10.0 vs 16.47 target (only 60.7% achievement)** — the biggest gap of any driver, consistent with rep detailing/HCP engagement being a live lever. Refill continuity loss and formulary access are the largest quantified drivers overall; competitor activity is the only negative (share-eroding) factor.
> 
> ## 2. Biologic-experienced vs. biologic-naive patients — **not available for Kisqali**
> The `biologic` breakdown axis exists only for **Remibrutinib** in this data model. Kisqali doesn't carry a biologic-status field (it's null by design), so I can't split the TRx decline by biologic-experienced vs. naive for Kisqali — I won't fabricate that split. If you need a comparable segmentation, `segment` (severity tier) or `therapy_line` are available axes for Kisqali.
> 
> ## 3. Next-quarter model outlook
> The `predictions` query didn't return a forward forecast with confidence intervals — it returned the latest recorded snapshot (2026-07-01) per brand/region. Treat these as the most recent read, not a validated forecast:
> - **Kisqali**: Northeast market share 0.49/0.57 target (86%), TRx (South) 203,508 vs 215,586 target (94.4%, YoY +30%). Northeast remains the weak spot on both share and engagement.
> - **Remibrutinib**: strong momentum — Northeast NRx 23,871 vs 21,799 target (**109.5% achievement**, YoY +40.4%, ROI 3.3), Northeast conversion rate 0.49 vs 0.49 target (**exactly at target**, YoY +12.5%).
> 
> ## 4. Data drift check
> The `drift_reports` query for both brands did **not** return actual drift diagnostics (no PSI/KS statistics or model-drift flags) — it returned the same KPI snapshot records as the predictions query. So I can't confirm or rule out data drift as a confound from what's available; if you need this, it likely requires a dedicated drift-monitoring agent/report that wasn't returned here. I'd flag this as an open gap before trusting the causal effect sizes too literally.
> 
> ## 5. Conversion rate check (Remibrutinib) — "stayed flat"
> Confirmed directionally: Remibrutinib Northeast conversion rate is **0.49 vs 0.49 target (100% achievement)**, up modestly YoY (+12.5%) — consistent with "flat" at target, not a specific quarter-over-quarter number (that calculation also failed to parse "last quarter"; re-run with e.g. "Q2 2026" if you want an exact figure).
> 
> ## Recommended experiment: rep-capacity test in the Northeast
> Given `rep_detailing_frequency → TRx volume (via HCP engagement)` has confidence 0.796, effect size 0.166, and a 77-day lag, and HCP engagement is only at 60.7% of target in the Northeast:
> 
> - **Design**: Geo-matched A/B test. Select Northeast territories with similar baseline TRx, market share, and formulary status; randomly assign to **treatment** (increased rep call frequency, e.g. +30–50% detailing visits) vs. **control** (current cadence).
> - **Primary endpoint**: TRx volume and HCP engagement score at 90 days (aligned to the 77-day observed lag).
> - **Secondary endpoints**: conversion rate, market share, refill continuity (persistent_180d) — to isolate whether rep capacity moves the engagement channel specifically vs. confounding with formulary/copay effects already in the causal chain.
> - **Control for confounds**: hold formulary status and copay program enrollment constant across arms (or stratify), since both are independently significant drivers (conf 0.805 and 0.794) that could otherwise contaminate the read.
> - **Power**: size the test using the $38,244 estimated impact of the detailing-frequency path as your minimum detectable effect basis.
> 
> Want me to pull the exact Kisqali Northeast TRx and Remibrutinib conversion rate for a specific quarter (e.g., "Q2 2026") so we have hard baseline numbers for the experiment brief?
